NCT04500522View on ClinicalTrials.gov

Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

September 15, 2021

Conditions

Infertility, Female

Interventions

DRUG

INH

3 vaginal tablet of isonicotinic acid hydrazide 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.

DRUG

Placebo

3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.

Trial Locations (1)

81528

Aswan University Hospital, Aswān

All Listed Sponsors

lead

Aswan University Hospital

OTHER

NCT04500522 - Vaginal Isonicotinic Acid Hydrazide Prior to Diagnostic Office Hysteroscopy in Primarily Infertile Patients | Biotech Hunter | Biotech Hunter